New York, NY -- (SBWIRE) -- 12/19/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: North American Palladium Ltd (USA) (NYSEMKT:PAL), GT Advanced Technologies Inc (NASDAQ:GTAT), CYS Investments Inc (NYSE:CYS), Opexa Therapeutics Inc (NASDAQ:OPXA)
North American Palladium Ltd (USA) (NYSEMKT:PAL) the stock opened the session at $0.47 but then moved to $0.470. At that price, the stock showed a positive performance of 11.90%. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. LDI is a primary producer of palladium. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals. The Company’s 100%-owned subsidiary is the Lac des Iles Mines Ltd. (LDI).
Will PAL Continue To Move Higher? Find Out Here
GT Advanced Technologies Inc (NASDAQ:GTAT) opened the session at $8.54 and closed the session at $8.49. The stock showed a negative performance of -0.12% in previous trading session. GT Advanced Technologies Inc. is diversified technology company with crystal growth equipment and solutions for the global solar, light emitting diode (LED) and electronics industries. The Company operates in three segments: its polysilicon business, its photovoltaic (PV), business and its sapphire business. The Company's principal products are Silicon Deposition Reactors (SDR) and related equipment used to produce polysilicon, the key raw material used in silicon-based solar wafers and cells;
Has GTAT Found The Bottom And Ready To Gain Momentum? Find Out Here
CYS Investments Inc (NYSE:CYS) opened the session at $7.38 and closed the session at $7.46. The stock showed a positive performance of 1.22% in previous trading session.. The beta of the stock remained 0.24. CYS Investments, Inc. is a specialty finance company created with the objective of achieving consistent risk-adjusted investment income. The Company invests in Agency residential mortgage-backed securities (RMBS) collateralized by fixed rate single-family residential mortgage loans (typically 15, 20 or 30 years), adjustable-rate mortgage loans (ARMs), which typically have coupon rates that reset monthly, or hybrid ARMs,
Why Should Investors Buy CYS After The Recent Gain? J ust Go Here and Find Out
Opexa Therapeutics Inc (NASDAQ:OPXA) the stock decreased -10.64% and finished the session at $1.68. Traded with volume of 3.58 million shares in the prior session and the average volume of the stock remained 571,235.00 shares. The beta of the stock remained 1.21. Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company’s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS.
Will OPXA Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)